Aethlon Medical, Inc. (Nasdaq: AEMD) filed a Current Report on Form 8-K on November 16, 2026, confirming the status of a previously announced business combination with North Immunology, Inc. The filing details a two-step merger structure involving Aethlon Medical, its wholly owned subsidiaries Nighthawk Merger Sub Corp. and Nighthawk Second Merger Sub, LLC, and North Immunology.
Under the terms of the Agreement and Plan of Merger and Reorganization, which was entered into on September 17, 2026, the transaction is structured as follows: First, Nighthawk Merger Sub Corp. will merge with and into North Immunology, with North Immunology surviving as a wholly owned subsidiary of Aethlon Medical. Immediately following this step, North Immunology will merge with and into Nighthawk Second Merger Sub, LLC, with the Second Merger Sub surviving the transaction.
The filing also references an updated investor presentation dated November 2026, attached as Exhibit 99.1. The presentation outlines the clinical profile of North Immunology’s lead candidate, NOR-101. NOR-101 is described as a half-life extended anti-IL-13 x IL-18 bispecific antibody designed to treat atopic dermatitis (AD). The presentation notes that the candidate targets both Th2 and non-Th2 inflammation and is expected to enter Phase 1a clinical trials in the first quarter of 2027.
The filing includes standard forward-looking statements regarding the structure, timing, and completion of the merger. It also warns of risks associated with the transaction, including the failure to obtain required stockholder approvals, the failure to complete a concurrent private placement, and the satisfaction of other closing conditions, such as Nasdaq approval of the initial listing application.